Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1. Preface
1.1. Objectives of the Study
1.2. Key Assumptions
1.3. Report Coverage – Key Segmentation and Scope
1.4. Research Methodology
2. Executive Summary
3. Acute Kidney Injury Market Overview – 8 Major Markets
3.1. Acute Kidney Injury Market Historical Value (2019-2025)
3.2. Acute Kidney Injury Market Forecast Value (2026-2035)
4. Vendor Positioning Analysis
4.1. Key Vendors
4.2. Prospective Leaders
4.3. Niche Leaders
4.4. Disruptors
5. Acute Kidney Injury Market: Disease Overview
5.1. Guidelines and Stages
5.2. Pathophysiology
5.3. Screening and Diagnosis
5.4. Treatment Pathway
6. Patient Profile
6.1. Patient Profile Overview
6.2. Patient Psychology and Emotional Impact Factors
6.3. Risk Assessment and Treatment Success Rate
7. Acute Kidney Injury Market - Epidemiology Scenario and Forecast – 8 Major Markets
7.1. 8MM Epidemiology Scenario Overview (2019-2035)
7.2. Prevalence, by Country
7.2.1. United States
7.2.2. United Kingdom
7.2.3. Germany
7.2.4. France
7.2.5. Italy
7.2.6. Spain
7.2.7. India
7.2.8. Japan
7.3. Diagnosed Cases, by Country
7.3.1. United States
7.3.2. United Kingdom
7.3.3. Germany
7.3.4. France
7.3.5. Italy
7.3.6. Spain
7.3.7. India
7.3.8. Japan
7.4. Treatment Seeking Rate, by Country
7.4.1. United States
7.4.2. United Kingdom
7.4.3. Germany
7.4.4. France
7.4.5. Italy
7.4.6. Spain
7.4.7. India
7.4.8. Japan
8. Acute Kidney Injury Market Landscape – 8 Major Markets
8.1. Acute Kidney Injury Market: Developers Landscape
8.1.1. Analysis by Year of Establishment
8.1.2. Analysis by Company Size
8.1.3. Analysis by Region
8.2. Acute Kidney Injury Market: Product Landscape
8.2.1. Analysis By Type
8.2.2. Analysis By Treatment Type
9. Clinical Trials and Pipeline Analysis
9.1. Analysis by Trial Registration Year
9.2. Analysis by Trial Status
9.3. Analysis by Trial Phase
9.4. Analysis by Therapeutic Area
9.5. Analysis by Geography
9.6. Drug Pipeline Analysis
10. Acute Kidney Injury Market Challenges and Unmet Needs
10.1. Treatment Pathway Challenges
10.2. Compliance and Drop-Out Analysis
10.3. Awareness and Prevention Gaps
11. Cost of Treatment
12. Acute Kidney Injury Market Dynamics
12.1. Market Drivers and Constraints
12.2. SWOT Analysis
12.2.1. Strengths
12.2.2. Weaknesses
12.2.3. Opportunities
12.2.4. Threats
12.3. PESTEL Analysis
12.3.1. Political
12.3.2. Economic
12.3.3. Social
12.3.4. Technological
12.3.5. Legal
12.3.6. Environment
12.4. Porter’s Five Forces Model
12.4.1. Bargaining Power of Suppliers
12.4.2. Bargaining Power of Buyers
12.4.3. Threat of New Entrants
12.4.4. Threat of Substitutes
12.4.5. Degree of Rivalry
12.5. Key Demand Indicators
12.6. Key Price Indicators
12.7. Industry Events, Initiatives, and Trends
12.8. Value Chain Analysis
13. Acute Kidney Injury Market Segmentation (2019-2035) - 8 Major Markets
13.1. Acute Kidney Injury Market (2019-2035) by Type
13.1.1. Market Overview
13.1.2. Prerenal Acute Kidney Injury
13.1.3. Intrinsic Renal Acute Kidney Injury
13.1.4. Postrenal Acute Kidney Injury
13.2. Acute Kidney Injury Market (2019-2035) by Treatment Type
13.2.1. Market Overview
13.2.2. Dialysis
13.2.2.1. Intermittent Hemodialysis
13.2.2.2. Continuous Renal Replacement Therapy (CRRT)
13.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
13.2.3. Drug Therapy
13.2.3.1. Antibiotics
13.2.3.2. Diuretics
13.2.3.3. Immunosuppressive Agents
13.3. Acute Kidney Injury Market (2019-2035) by End User
13.3.1. Market Overview
13.3.2. Hospitals
13.3.3. Specialty Clinics
13.3.4. Ambulatory Surgical Centers
13.3.5. Others
13.4. Acute Kidney Injury Market (2019-2035) by Region
13.4.1. Market Overview
13.4.2. United States
13.4.3. United Kingdom
13.4.4. Germany
13.4.5. France
13.4.6. Italy
13.4.7. Spain
13.4.8. Japan
13.4.9. India
14. United States Acute Kidney Injury Market (2019-2035)
14.1. United States Acute Kidney Injury Market (2019-2035) by Type
14.1.1. Market Overview
14.1.2. Prerenal Acute Kidney Injury
14.1.3. Intrinsic Renal Acute Kidney Injury
14.1.4. Postrenal Acute Kidney Injury
14.2. United States Acute Kidney Injury Market (2019-2035) by Treatment Type
14.2.1. Market Overview
14.2.2. Dialysis
14.2.2.1. Intermittent Hemodialysis
14.2.2.2. Continuous Renal Replacement Therapy (CRRT)
14.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
14.2.3. Drug Therapy
14.2.3.1. Antibiotics
14.2.3.2. Diuretics
14.2.3.3. Immunosuppressive Agents
14.3. United States Acute Kidney Injury Market (2019-2035) by End User
14.3.1. Market Overview
14.3.2. Hospitals
14.3.3. Specialty Clinics
14.3.4. Ambulatory Surgical Centers
14.3.5. Others
15. United Kingdom Acute Kidney Injury Market (2019-2035)
15.1. United Kingdom Acute Kidney Injury Market (2019-2035) by Type
15.1.1. Market Overview
15.1.2. Prerenal Acute Kidney Injury
15.1.3. Intrinsic Renal Acute Kidney Injury
15.1.4. Postrenal Acute Kidney Injury
15.2. United Kingdom Acute Kidney Injury Market (2019-2035) by Treatment Type
15.2.1. Market Overview
15.2.2. Dialysis
15.2.2.1. Intermittent Hemodialysis
15.2.2.2. Continuous Renal Replacement Therapy (CRRT)
15.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
15.2.3. Drug Therapy
15.2.3.1. Antibiotics
15.2.3.2. Diuretics
15.2.3.3. Immunosuppressive Agents
15.3. United Kingdom Acute Kidney Injury Market (2019-2035) by End User
15.3.1. Market Overview
15.3.2. Hospitals
15.3.3. Specialty Clinics
15.3.4. Ambulatory Surgical Centers
15.3.5. Others
16. Germany Acute Kidney Injury Market (2019-2035)
16.1. Germany Acute Kidney Injury Market (2019-2035) by Type
16.1.1. Market Overview
16.1.2. Prerenal Acute Kidney Injury
16.1.3. Intrinsic Renal Acute Kidney Injury
16.1.4. Postrenal Acute Kidney Injury
16.2. Germany Acute Kidney Injury Market (2019-2035) by Treatment Type
16.2.1. Market Overview
16.2.2. Dialysis
16.2.2.1. Intermittent Hemodialysis
16.2.2.2. Continuous Renal Replacement Therapy (CRRT)
16.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
16.2.3. Drug Therapy
16.2.3.1. Antibiotics
16.2.3.2. Diuretics
16.2.3.3. Immunosuppressive Agents
16.3. Germany Acute Kidney Injury Market (2019-2035) by End User
16.3.1. Market Overview
16.3.2. Hospitals
16.3.3. Specialty Clinics
16.3.4. Ambulatory Surgical Centers
16.3.5. Others
17. France Acute Kidney Injury Market (2019-2035)
17.1. France Acute Kidney Injury Market (2019-2035) by Type
17.1.1. Market Overview
17.1.2. Prerenal Acute Kidney Injury
17.1.3. Intrinsic Renal Acute Kidney Injury
17.1.4. Postrenal Acute Kidney Injury
17.2. France Acute Kidney Injury Market (2019-2035) by Treatment Type
17.2.1. Market Overview
17.2.2. Dialysis
17.2.2.1. Intermittent Hemodialysis
17.2.2.2. Continuous Renal Replacement Therapy (CRRT)
17.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
17.2.3. Drug Therapy
17.2.3.1. Antibiotics
17.2.3.2. Diuretics
17.2.3.3. Immunosuppressive Agents
17.3. France Acute Kidney Injury Market (2019-2035) by End User
17.3.1. Market Overview
17.3.2. Hospitals
17.3.3. Specialty Clinics
17.3.4. Ambulatory Surgical Centers
17.3.5. Others
18. Italy Acute Kidney Injury Market (2019-2035)
18.1. Italy Acute Kidney Injury Market (2019-2035) by Type
18.1.1. Market Overview
18.1.2. Prerenal Acute Kidney Injury
18.1.3. Intrinsic Renal Acute Kidney Injury
18.1.4. Postrenal Acute Kidney Injury
18.2. Italy Acute Kidney Injury Market (2019-2035) by Treatment Type
18.2.1. Market Overview
18.2.2. Dialysis
18.2.2.1. Intermittent Hemodialysis
18.2.2.2. Continuous Renal Replacement Therapy (CRRT)
18.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
18.2.3. Drug Therapy
18.2.3.1. Antibiotics
18.2.3.2. Diuretics
18.2.3.3. Immunosuppressive Agents
18.3. Italy Acute Kidney Injury Market (2019-2035) by End User
18.3.1. Market Overview
18.3.2. Hospitals
18.3.3. Specialty Clinics
18.3.4. Ambulatory Surgical Centers
18.3.5. Others
19. Spain Acute Kidney Injury Market (2019-2035)
19.1. Spain Acute Kidney Injury Market (2019-2035) by Type
19.1.1. Market Overview
19.1.2. Prerenal Acute Kidney Injury
19.1.3. Intrinsic Renal Acute Kidney Injury
19.1.4. Postrenal Acute Kidney Injury
19.2. Spain Acute Kidney Injury Market (2019-2035) by Treatment Type
19.2.1. Market Overview
19.2.2. Dialysis
19.2.2.1. Intermittent Hemodialysis
19.2.2.2. Continuous Renal Replacement Therapy (CRRT)
19.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
19.2.3. Drug Therapy
19.2.3.1. Antibiotics
19.2.3.2. Diuretics
19.2.3.3. Immunosuppressive Agents
19.3. Spain Acute Kidney Injury Market (2019-2035) by End User
19.3.1. Market Overview
19.3.2. Hospitals
19.3.3. Specialty Clinics
19.3.4. Ambulatory Surgical Centers
19.3.5. Others
20. Japan Acute Kidney Injury Market (2019-2035)
20.1. Japan Acute Kidney Injury Market (2019-2035) by Type
20.1.1. Market Overview
20.1.2. Prerenal Acute Kidney Injury
20.1.3. Intrinsic Renal Acute Kidney Injury
20.1.4. Postrenal Acute Kidney Injury
20.2. Japan Acute Kidney Injury Market (2019-2035) by Treatment Type
20.2.1. Market Overview
20.2.2. Dialysis
20.2.2.1. Intermittent Hemodialysis
20.2.2.2. Continuous Renal Replacement Therapy (CRRT)
20.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
20.2.3. Drug Therapy
20.2.3.1. Antibiotics
20.2.3.2. Diuretics
20.2.3.3. Immunosuppressive Agents
20.3. Japan Acute Kidney Injury Market (2019-2035) by End User
20.3.1. Market Overview
20.3.2. Hospitals
20.3.3. Specialty Clinics
20.3.4. Ambulatory Surgical Centers
20.3.5. Others
21. India Acute Kidney Injury Market (2019-2035)
21.1. India Acute Kidney Injury Market (2019-2035) by Type
21.1.1. Market Overview
21.1.2. Prerenal Acute Kidney Injury
21.1.3. Intrinsic Renal Acute Kidney Injury
21.1.4. Postrenal Acute Kidney Injury
21.2. India Acute Kidney Injury Market (2019-2035) by Treatment Type
21.2.1. Market Overview
21.2.2. Dialysis
21.2.2.1. Intermittent Hemodialysis
21.2.2.2. Continuous Renal Replacement Therapy (CRRT)
21.2.2.3. Sustained Low-Efficiency Dialysis (SLED)
21.2.3. Drug Therapy
21.2.3.1. Antibiotics
21.2.3.2. Diuretics
21.2.3.3. Immunosuppressive Agents
21.3. India Acute Kidney Injury Market (2019-2035) by End User
21.3.1. Market Overview
21.3.2. Hospitals
21.3.3. Specialty Clinics
21.3.4. Ambulatory Surgical Centers
21.3.5. Others
22. Regulatory Framework
22.1. Regulatory Overview
22.2. US FDA
22.3. EU EMA
22.4. Japan PMDA
22.5. India CDSCO
22.6. Others
23. Patent Analysis
23.1. Analysis by Type of Patent
23.2. Analysis by Publication Year
23.3. Analysis by Issuing Authority
23.4. Analysis by Patent Age
23.5. Analysis by CPC Analysis
23.6. Analysis by Patent Valuation
24. Grants Analysis
24.1. Analysis by Year
24.2. Analysis by Amount Awarded
24.3. Analysis by Issuing Authority
24.4. Analysis by Grant Application
24.5. Analysis by Funding Institute
24.6. Analysis by NIH Departments
24.7. Analysis by Recipient Organization
25. Funding and Investment Analysis
25.1. Analysis by Funding Instances
25.2. Analysis by Drug Class of Funding
25.3. Analysis by Funding Amount
25.4. Analysis by Leading Players
25.5. Analysis by Leading Investors
25.6. Analysis by Geography
26. Strategic Initiatives
26.1. Analysis by Partnership Instances
26.2. Analysis by Drug Class of Partnership
26.3. Analysis by Leading Players
26.4. Analysis by Geography
27. Supplier Landscape
27.1. Market Share Analysis, By Region for Top 5 Companies
27.2. Pfizer Inc .
27.2.1. Financial Analysis
27.2.2. Product Portfolio
27.2.3. Demographic Reach and Achievements
27.2.4. Company News and Development
27.2.5. Certifications
27.3. Baxter International, Inc .
27.3.1. Financial Analysis
27.3.2. Product Portfolio
27.3.3. Demographic Reach and Achievements
27.3.4. Company News and Development
27.3.5. Certifications
27.4. Asahi Kasei Medical Co., Ltd.
27.4.1. Financial Analysis
27.4.2. Product Portfolio
27.4.3. Demographic Reach and Achievements
27.4.4. Company News and Development
27.4.5. Certifications
27.5. B. Braun Melsungen AG
27.5.1. Financial Analysis
27.5.2. Product Portfolio
27.5.3. Demographic Reach and Achievements
27.5.4. Company News and Development
27.5.5. Certifications
27.6. Quark Pharmaceuticals, Inc.
27.6.1. Financial Analysis
27.6.2. Product Portfolio
27.6.3. Demographic Reach and Achievements
27.6.4. Company News and Development
27.6.5. Certifications
27.7. Asahi Kasei Medical Co., Ltd.
27.7.1. Financial Analysis
27.7.2. Product Portfolio
27.7.3. Demographic Reach and Achievements
27.7.4. Company News and Development
27.7.5. Certifications
27.8. B. Braun Melsungen AG
27.8.1. Financial Analysis
27.8.2. Product Portfolio
27.8.3. Demographic Reach and Achievements
27.8.4. Company News and Development
27.8.5. Certifications
27.9. Quark Pharmaceuticals, Inc.
27.9.1. Financial Analysis
27.9.2. Product Portfolio
27.9.3. Demographic Reach and Achievements
27.9.4. Company News and Development
27.9.5. Certifications
28. Acute Kidney Injury Market - Distribution Model (Additional Insight)
28.1. Overview
28.2. Potential Distributors
28.3. Key Parameters for Distribution Partner Assessment
29. Key Opinion Leaders (KOL) Insights (Additional Insight)
30. Payment Methods (Additional Insight)
30.1. Government Funded
30.2. Private Insurance
30.3. Out-of-Pocket
*The list of players in the competitive landscape section can be customised or made more exhaustive based on your specific requirements.*